I am a pharmaceutical scientist with a PhD from the University of Padua, where my dissertation focused on the Development of Target-specific and Tumor-selective Metallodrugs. My research has been centered on designing and evaluating metal-based anticancer agents, including complexes of copper, silver, gold, and iron, with the goal of achieving high tumor selectivity while minimizing toxicity. A key component of my work is the study of structure–activity relationships (SAR), which guides rational drug design and the optimization of new compounds. Currently, I am a Research Fellow in the Jason Lewis Laboratory at Memorial Sloan Kettering Cancer Center in New York, where I develop and evaluate theranostic radiopharmaceuticals based on the copper isotope pair 64Cu/67Cu. This approach combines diagnostic imaging with targeted therapy, allowing precise tumor visualization and personalized treatment strategies. My research focuses on creating agents with high stability, selectivity, and translational potential, bridging the fields of coordination chemistry, pharmacology, and nuclear medicine. Overall, my aim is to contribute to the advancement of metal-based therapeutics and copper-based theranostics, developing innovative tools for precision oncology that offer more effective and selective options for diagnosing and treating cancer.